Sign In
Buy SLS
$8.23
-0.81 (-8.96%)
At Close: Jun 05, 2026
- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS''
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
08:06pm, Thursday, 31'st Jul 2025
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
08:45am, Monday, 07'th Jul 2025
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 23'rd Jun 2025
Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
08:45am, Thursday, 05'th Jun 2025
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year New appointments of Drs. Philip C. Amr
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
08:00am, Monday, 02'nd Jun 2025
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
08:00am, Tuesday, 20'th May 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
08:45am, Thursday, 15'th May 2025
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) - First ASXL1 Pediatric Acute Myeloid Le
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 13'th May 2025
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC an
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
08:45am, Monday, 28'th Apr 2025
New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells New Data Suggest SLS009 (tambiciclib) May Overcome Resis
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
10:23am, Wednesday, 23'rd Apr 2025
- ASCO Presentation to Highlight Preclinical Efficacy of SLS009 (tambiciclib) in ASXL1 Mutated Colorectal Cancer - - ASCO Presentation to Highlight Preclinical Efficacy of SLS009 (tambiciclib) in ASXL
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
08:45am, Tuesday, 08'th Apr 2025
- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing His
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
03:03pm, Monday, 31'st Mar 2025
Sellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML. Interim results for GPS are promising but
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
04:05pm, Thursday, 20'th Mar 2025
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Eve
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
08:45am, Thursday, 20'th Feb 2025
- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients -
